Nov 07, 2024 8:47am EST MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement
Nov 05, 2024 9:45am EST MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Oct 15, 2024 8:15am EDT MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics
Sep 10, 2024 6:00am EDT MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer
Sep 04, 2024 8:30am EDT MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference
Jul 23, 2024 4:11am EDT MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent
Jun 07, 2024 12:31pm EDT MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA’s Approval of a Telomerase Inhibitor Agent Therapy
Jun 06, 2024 10:07am EDT MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent
Jun 04, 2024 8:41am EDT MAIA Biotechnology Reveals New Clinical Data Showing THIO’s Strong Efficacy in Non-Small Cell Lung Cancer
